TITLE

Questcor Defies Market Turmoil, Works On New Base

AUTHOR(S)
SCOTT STODDARD
PUB. DATE
February 2014
SOURCE
Investors Business Daily;2/ 3/2014, pB11
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Market in correction?
ACCESSION #
94193432

 

Related Articles

  • Healthcare: Don Bailey. REED, VITA // Orange County Business Journal;1/6/2014, Vol. 37 Issue 1, p5 

    The article cites Don Bailey, chief executive officer (CEO) of Anaheim, California-based drug maker Questcor Pharmaceuticals Inc., who managed to make the company's shares increase despite controversies.

  • QUESTCOR PHARMACEUTICALS INC.  // MondayMorning;10/ 1/2012, Vol. 20 Issue 37, p1 

    The article reports that Questcor Pharmaceuticals Inc. has been investigated by U.S. agency regarding its marketing strategy and possible generic threat to Acthar. It states that the investigation is due to the concerns raised by Citron Research and Andrew Left on the company's promotional...

  • Anaheim Lands HQ of Bay Area Drug Maker. Reed, Vita // Orange County Business Journal;10/25/2010, Vol. 33 Issue 43, p1 

    The article reports on the business relocation of Questcor Pharmaceuticals Inc. in Anaheim Hills, California. It states that the company moved its location to be closer to its chief executive officer (CEO) Don Bailey. It notes that the company is temporarily based near Weir Canyon Road and the...

  • Lucky Man: CEO's Repeated Good Fortune in Timing Stock Sales. Eisinger, Jesse // Pro Publica;2/1/2014, p18 

    The article features U.S.-based Questcor Pharmaceuticals Inc., a biotechnology firm with a $4 billion market capitalization. It highlights a significant event for Questcor when its chief executive officer (CEO) Don M. Bailey sells stock through his regular selling plans. It notes that several...

  • CEO Don Bailey's Gambit. SCOTT S. SMITH // Investors Business Daily;10/18/2013, pA03 

    When Don Bailey took the helm of Questcor Pharmaceuticals as interim CEO in May 2007, the firm seemed on its deathbed.

  • Questcor Expected to Stay After $5.6B Sale. REED, VITA // Orange County Business Journal;4/14/2014, Vol. 37 Issue 15, p1 

    The article reports on the plan of pharmaceutical company Mallinckrodt to retain the commercial operations of drug maker Questcor Pharmaceutical Inc. as a separate business unit following its $5.6 billion sale. Topics discussed include the offer of Mallinckrodt, the sales of Questcor as of 2014,...

  • Questcor Switches to Quarterly Prescription Updates. Reed, Vita // Orange County Business Journal;11/5/2012, Vol. 35 Issue 45, p50 

    The article provides information on Questcor Pharmaceuticals Inc.'s decision to provide the prescription numbers for its H.P. Acthar Gel in a quarterly report rather than in a monthly report. According to Don Bailey, the chief executive officer of the company, prescriptions and saleshave reached...

  • QUESTCOR EXPANDS EMITASOL LICENSE WITH AHN-GOOK.  // Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p1 

    Reports on the expansion of the license agreement between Questcor Pharmaceuticals Inc. and Ahn-Gook Pharmaceutical Co. Ltd., as of February 2003.

  • Questcor Eyes More Conditions for Core Drug Acthar. Reed, Vita // Orange County Business Journal;6/27/2011, Vol. 34 Issue 26, p28 

    The article reports on the plan of Anaheim, California-based Questcor Pharmaceuticals Inc. to market its Acthar drug for a wide range of pathological conditions that are difficult to manage.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics